Literature DB >> 15554582

Influence of behavioral symptoms on rates of institutionalization for persons with Alzheimer's disease.

D W Gilley1, J L Bienias, R S Wilson, D A Bennett, T L Beck, D A Evans.   

Abstract

BACKGROUND: Recent studies indicate that behavioral symptoms may play a key role in decisions to institutionalize persons with Alzheimer's disease (AD), but the specific types of behavior that contribute to this increased risk have not been reliably identified. The relationship between behavioral symptoms and time to institutionalization was evaluated in a 4-year longitudinal study.
METHOD: A total of 410 persons with the clinical diagnosis of AD completed annual clinical evaluations to assess cognitive impairment, functional limitations, delusions, hallucinations, depressive symptoms and physical aggression. Participation rates among survivors exceeded 90% for four follow-up evaluations with complete ascertainment of mortality and institutionalization. Time to institutionalization was evaluated using proportional hazards regression models in relation to time-varying clinical features.
RESULTS: In multivariate models, adjusted for demographic and social variables, four clinical features emerged as the predominant predictors of institutionalization: cognitive impairment level, physical aggression, hallucinations and depressive symptoms. These associations were virtually unchanged in analyses controlling for mortality.
CONCLUSIONS: Specific behavioral symptoms are important independent risk factors for institutionalization in persons with AD. Because behavioral symptoms are susceptible to therapy, efforts to modify or prevent these symptoms deserve careful consideration as a means to delay institutionalization for persons with this disease.

Entities:  

Mesh:

Year:  2004        PMID: 15554582     DOI: 10.1017/s0033291703001831

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  31 in total

Review 1.  Non-pharmacological Management of Behavioral Symptoms in Frontotemporal and Other Dementias.

Authors:  Cynthia Barton; Robin Ketelle; Jennifer Merrilees; Bruce Miller
Journal:  Curr Neurol Neurosci Rep       Date:  2016-02       Impact factor: 5.081

2.  Developing a Measurement Strategy for Assessing Family Caregiver Skills: Conceptual Issues.

Authors:  Carol J Farran; Judith J McCann; Louis G Fogg; Caryn D Etkin
Journal:  Alzheimers care today       Date:  2009

3.  Nonpharmacologic management of behavioral symptoms in dementia.

Authors:  Laura N Gitlin; Helen C Kales; Constantine G Lyketsos
Journal:  JAMA       Date:  2012-11-21       Impact factor: 56.272

4.  Ginkgo biloba extract EGb 761 in the treatment of dementia: a pharmacoeconomic analysis of the Austrian setting.

Authors:  Michael Rainer; Hermann Mucke; Sandra Schlaefke
Journal:  Wien Klin Wochenschr       Date:  2013-01-05       Impact factor: 1.704

5.  Comparison of neuropsychiatric symptoms and diffusion tensor imaging correlates among patients with subcortical ischemic vascular disease and Alzheimer's disease.

Authors:  Min-Chien Tu; Wen-Hui Huang; Yen-Hsuan Hsu; Chung-Ping Lo; Jie Fu Deng; Ching-Feng Huang
Journal:  BMC Neurol       Date:  2017-07-28       Impact factor: 2.474

6.  Frontolimbic atrophy is associated with agitation and aggression in mild cognitive impairment and Alzheimer's disease.

Authors:  Paula T Trzepacz; Peng Yu; Phani K Bhamidipati; Brian Willis; Tammy Forrester; Linda Tabas; Adam J Schwarz; Andrew J Saykin
Journal:  Alzheimers Dement       Date:  2012-12-17       Impact factor: 21.566

7.  Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease.

Authors:  Paula T Trzepacz; Jeffrey Cummings; Thomas Konechnik; Tammy D Forrester; Curtis Chang; Ellen B Dennehy; Brian A Willis; Catherine Shuler; Linda B Tabas; Constantine Lyketsos
Journal:  Int Psychogeriatr       Date:  2012-12-21       Impact factor: 3.878

8.  Practice constraints, behavioral problems, and dementia care: primary care physicians' perspectives.

Authors:  Ladson Hinton; Carol E Franz; Geetha Reddy; Yvette Flores; Richard L Kravitz; Judith C Barker
Journal:  J Gen Intern Med       Date:  2007-09-07       Impact factor: 5.128

9.  Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease.

Authors:  O L Lopez; J T Becker; A S Wahed; J Saxton; R A Sweet; D A Wolk; W Klunk; S T Dekosky
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-02-09       Impact factor: 10.154

10.  Aggression and violence among elderly patients, a growing health problem.

Authors:  Jeffrey L Jaclson; Renee Mallory
Journal:  J Gen Intern Med       Date:  2009-10       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.